| pubmed-article:1384952 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0376562 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0025677 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0042670 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0151942 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:1384952 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:1384952 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:1384952 | pubmed:dateCreated | 1992-12-11 | lld:pubmed |
| pubmed-article:1384952 | pubmed:abstractText | Combination chemotherapy with a regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) has produced long-term survival times in a significant proportion of patients with advanced nodal and metastatic urothelial tumors. The availability of the colony-stimulating factors has spurred interest in studies evaluating escalated dosing schedules of M-VAC in an attempt to improve major response rates and overall survival. More frequent use of the colony-stimulating factors, however, in this and other settings may be associated with unrecognized side effects. The authors report a case of arterial thrombosis in a 69-year-old man receiving recombinant granulocyte colony-stimulating factor (rhG-CSF) and escalated-dose M-VAC for treatment of a transitional cell carcinoma of the bladder. Incidents of venous thrombosis have been reported previously with the use of colony-stimulating factors, but, to the knowledge of the authors, this case represents the first report of an arterial thrombosis occurring in a patient receiving rhG-CSF. | lld:pubmed |
| pubmed-article:1384952 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1384952 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1384952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1384952 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1384952 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:1384952 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:1384952 | pubmed:author | pubmed-author:ConteJ EJE | lld:pubmed |
| pubmed-article:1384952 | pubmed:author | pubmed-author:ScherH IHI | lld:pubmed |
| pubmed-article:1384952 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1384952 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:1384952 | pubmed:volume | 70 | lld:pubmed |
| pubmed-article:1384952 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1384952 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1384952 | pubmed:pagination | 2699-702 | lld:pubmed |
| pubmed-article:1384952 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:meshHeading | pubmed-meshheading:1384952-... | lld:pubmed |
| pubmed-article:1384952 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1384952 | pubmed:articleTitle | Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. | lld:pubmed |
| pubmed-article:1384952 | pubmed:affiliation | Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021. | lld:pubmed |
| pubmed-article:1384952 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1384952 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1384952 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1384952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1384952 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1384952 | lld:pubmed |
